These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 25955225)

  • 1. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis.
    Chen CL; Chen NC; Hsu CY; Chou KJ; Lee PT; Fang HC; Renn JH
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2426-32. PubMed ID: 24670088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
    Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of calcitriol on secondary hyperparathyroidism].
    Xu H; Zhang J; Cheng X; Zhou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients.
    Huraib S; Abu-Aisha H; Abed J; Al Wakeel J; Al Desouki M; Memon N
    Am J Nephrol; 1997; 17(2):118-23. PubMed ID: 9096441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy.
    Torregrosa JV; Fuster D; Ybarra J; Ortín J; Moreno A; Valveny N
    Am J Kidney Dis; 2004 Sep; 44(3):476-80. PubMed ID: 15332220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
    Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V
    Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
    Yuan F; Chen X; Wang C; Zhou A; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microwave ablation: an effective treatment for mild-to-moderate secondary hyperparathyroidism in patients undergoing haemodialysis.
    Wang G; Liu S; Liu X; Qian L; Diao Z; Liu W
    Int J Hyperthermia; 2017 Dec; 33(8):946-952. PubMed ID: 28768451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.